RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Sinphar Pharmaceutical Co EBIT 2024

Sinphar Pharmaceutical Co EBIT

286.06 M TWD

Sinphar Pharmaceutical Co Dividend yield

2.71 %

Ticker

1734.TW

ISIN

TW0001734002

In 2024, Sinphar Pharmaceutical Co's EBIT was 286.06 M TWD, a 44.96% increase from the 197.34 M TWD EBIT recorded in the previous year.

The Sinphar Pharmaceutical Co EBIT history

YEAREBIT (undefined TWD)
2023286.06
2022197.34
2021-182.8
2020-122.2
2019-147
2018-119.3
2017-63
2016-142.2
2015-128.2
2014144.3
2013162.5
2012126.2
201162.6
201097.3
2009134.9
200863.1
200786.1
200641.1
2005137
2004131.9

Sinphar Pharmaceutical Co Aktienanalyse

What does Sinphar Pharmaceutical Co do?

Sinphar Pharmaceutical Co Ltd is a Taiwanese company specializing in the pharmaceutical industry, founded in 1970. It is a leading manufacturer of pharmaceuticals and specializes in the production of generics and branded drugs. The company is headquartered in Taipei, Taiwan and has become an important player in the global pharmaceutical market in recent years. It has several divisions specializing in the production of drugs, supplements, and medical devices. Sinphar has two main business models, including the development of its own products and the licensing of products from other companies. The company has its own manufacturing facility, certified to FDA and GMP (Good Manufacturing Practice) standards, allowing it to produce high-quality drugs. Sinphar offers a wide range of products, including pharmaceuticals, supplements, medical devices, and other health products. It also has a variety of products focusing on the treatment of diseases such as diabetes, cancer, heart disease, and other conditions. The company has several divisions specializing in the development of drugs and medical devices. It also has an extensive research and development department focusing on the development of new drugs and medical devices. Sinphar works closely with various academic institutions and research institutes to stay updated on the latest developments in medicine and utilize the latest technologies. The company has several subsidiaries, including ones in the USA, China, and Singapore. Through these subsidiaries, the company has access to various local markets and can sell its products worldwide. Sinphar has received several awards and recognition for its work in recent years. In 2019, the company was awarded by the Taiwanese Ministry of Education for its exceptional performance in the development of medical devices and pharmaceutical products. Overall, Sinphar Pharmaceutical Co Ltd is a leading player in the pharmaceutical industry with a long history of developing high-quality drugs and medical devices. It specializes in the production of generics and branded drugs and has several divisions specializing in the development of drugs and medical devices. With its subsidiaries and research and development department, the company is well positioned to continue growing and evolving in the future. Sinphar Pharmaceutical Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Sinphar Pharmaceutical Co's EBIT

Sinphar Pharmaceutical Co's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Sinphar Pharmaceutical Co's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Sinphar Pharmaceutical Co's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Sinphar Pharmaceutical Co’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Sinphar Pharmaceutical Co Stock

How much did Sinphar Pharmaceutical Co achieve in EBIT for the current year?

In the current year, Sinphar Pharmaceutical Co has achieved an EBIT of 286.06 M TWD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Sinphar Pharmaceutical Co.

How has the EBIT of Sinphar Pharmaceutical Co developed in recent years?

The EBIT of Sinphar Pharmaceutical Co has increased by 44.96% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Sinphar Pharmaceutical Co?

The EBIT of Sinphar Pharmaceutical Co is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Sinphar Pharmaceutical Co pay?

Over the past 12 months, Sinphar Pharmaceutical Co paid a dividend of 1 TWD . This corresponds to a dividend yield of about 2.71 %. For the coming 12 months, Sinphar Pharmaceutical Co is expected to pay a dividend of 1 TWD.

What is the dividend yield of Sinphar Pharmaceutical Co?

The current dividend yield of Sinphar Pharmaceutical Co is 2.71 %.

When does Sinphar Pharmaceutical Co pay dividends?

Sinphar Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of August, September, August, August.

How secure is the dividend of Sinphar Pharmaceutical Co?

Sinphar Pharmaceutical Co paid dividends every year for the past 20 years.

What is the dividend of Sinphar Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to 1 TWD are expected. This corresponds to a dividend yield of 2.71 %.

In which sector is Sinphar Pharmaceutical Co located?

Sinphar Pharmaceutical Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Sinphar Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Sinphar Pharmaceutical Co from 8/18/2023 amounting to 1 TWD, you needed to have the stock in your portfolio before the ex-date on 7/13/2023.

When did Sinphar Pharmaceutical Co pay the last dividend?

The last dividend was paid out on 8/18/2023.

What was the dividend of Sinphar Pharmaceutical Co in the year 2023?

In the year 2023, Sinphar Pharmaceutical Co distributed 0.2 TWD as dividends.

In which currency does Sinphar Pharmaceutical Co pay out the dividend?

The dividends of Sinphar Pharmaceutical Co are distributed in TWD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Sinphar Pharmaceutical Co

Our stock analysis for Sinphar Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sinphar Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.